Literature DB >> 15670932

NMR conformational analysis of p-tolyl furanopyrimidine 2'-deoxyribonucleoside and crystal structure of its 3',5'-di-O-acetyl derivative.

Noor Esho1, Jean-Paul Desaulniers, Brian Davies, Helen M-P Chui, Meneni Srinivasa Rao, Christine S Chow, Slawomir Szafert, Roman Dembinski.   

Abstract

The conformation of a representative molecule of a new, potent class of antiviral-active modified nucleosides is determined. A bicyclic nucleoside, 3-(2'-deoxy-beta-D-ribofuranosyl)-6-(4-methylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one, shows C2'-endo and C3'-endo ribose conformations in solution (63:37, 37 degrees C; DMSO-d6), as determined by 1H NMR studies. The crystal structure of a 3',5'-di-O-acetyl-protected derivative (monoclinic, P21, a/b/c= 6.666(1)/12.225(1)/24.676(2) A, beta=90.24(1) degrees , Z=4) shows exclusively C2'-endo deoxyribose puckering. The base is found in the anti position both in solution and in crystalline form.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670932     DOI: 10.1016/j.bmc.2004.11.013

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

Review 1.  Transition metal-mediated synthesis of monocyclic aromatic heterocycles.

Authors:  Anton V Gulevich; Alexander S Dudnik; Natalia Chernyak; Vladimir Gevorgyan
Journal:  Chem Rev       Date:  2013-01-10       Impact factor: 60.622

2.  Synthesis and EPR studies of 2'-deoxyuridines with alkynyl, rodlike linkages.

Authors:  Adam Sniady; Michael D Sevilla; Srinivasarao Meneni; Tadeusz Lis; Slawomir Szafert; Deepthi Khanduri; John M Finke; Roman Dembinski
Journal:  Chemistry       Date:  2009-08-03       Impact factor: 5.236

3.  Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups.

Authors:  Renata Kaczmarek; Dylan J Twardy; Trevor L Olson; Dariusz Korczyński; Graciela Andrei; Robert Snoeck; Rafał Dolot; Kraig A Wheeler; Roman Dembinski
Journal:  Eur J Med Chem       Date:  2020-09-28       Impact factor: 6.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.